Literature DB >> 9368778

T cell defined tumor antigens.

B J Van den Eynde1, P van der Bruggen.   

Abstract

T cell defined antigens have now been characterized in a large variety of tumor types, in both mice and humans. An increasing number of these antigens appear to result from tumor-specific mutations, and some of these mutations may be implicated in oncogenesis. The priority is now to demonstrate that immunization against some of these antigens is clinically valuable for antitumor therapy, and the first results of clinical pilot studies are now emerging.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9368778     DOI： 10.1016/s0952-7915(97)80050-7

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN： 0952-7915            Impact factor:   7.486


  99 in total

1.  Identification of naturally processed and HLA-presented Epstein-Barr virus peptides recognized by CD4(+) or CD8(+) T lymphocytes from human blood.

Authors:  W Herr; E Ranieri; A Gambotto; L S Kierstead; A A Amoscato; L Gesualdo; W J Storkus
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-12       Impact factor: 11.205

Review 2.  T cell receptor usage in malignant diseases.

Authors:  E Halapi; M Jeddi-Tehrani; A Osterborg; H Mellstedt
Journal:  Springer Semin Immunopathol       Date:  1999

3.  The Waardenburg syndrome type 4 gene, SOX10, is a novel tumor-associated antigen identified in a patient with a dramatic response to immunotherapy.

Authors:  Hung T Khong; Steven A Rosenberg
Journal:  Cancer Res       Date:  2002-06-01       Impact factor: 12.701

4.  Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells.

Authors:  C Yee; J A Thompson; D Byrd; S R Riddell; P Roche; E Celis; P D Greenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-11       Impact factor: 11.205

5.  Immune response after photodynamic therapy increases anti-cancer and anti-bacterial effects.

Authors:  Eleonora Reginato; Peter Wolf; Michael R Hamblin
Journal:  World J Immunol       Date:  2014-03-27

6.  Identification of a major histocompatibility complex class I-restricted T-cell epitope in the tumour-associated antigen, 5T4.

Authors:  Irina Redchenko; Richard Harrop; Matthew G Ryan; Robert E Hawkins; Miles W Carroll
Journal:  Immunology       Date:  2006-05       Impact factor: 7.397

Review 7.  Regulation of tumour immunity by CD25+ T cells.

Authors:  Awen Gallimore; Shimon Sakaguchi
Journal:  Immunology       Date:  2002-09       Impact factor: 7.397

8.  Evaluation of the modified ELISPOT assay for gamma interferon production in cancer patients receiving antitumor vaccines.

Authors:  T Asai; W J Storkus; T L Whiteside
Journal:  Clin Diagn Lab Immunol       Date:  2000-03

Review 9.  Prospects and challenges of building a cancer vaccine targeting telomerase.

Authors:  Robert H Vonderheide
Journal:  Biochimie       Date:  2007-07-17       Impact factor: 4.079

10.  A Mage3/Heat Shock Protein70 DNA vaccine induces both innate and adaptive immune responses for the antitumor activity.

Authors:  Lifeng Wang; Lisa Rollins; Qinlong Gu; Si-Yi Chen; Xue F Huang
Journal:  Vaccine       Date:  2009-10-14       Impact factor: 3.641
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.